KHK 2866

Drug Profile

KHK 2866

Alternative Names: KHK2866

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Kyowa Hakko Kirin
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Heparin binding EGF like growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Ovarian cancer; Solid tumours

Most Recent Events

  • 17 Apr 2013 Discontinued - Phase-I for Ovarian cancer in USA (IV)
  • 05 Mar 2013 Kyowa Hakko Kirin Pharma terminates its phase I trial in Solid tumours including Ovarian cancer in USA (NCT01279291)
  • 11 Jan 2011 Phase-I clinical trials in Ovarian cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top